期刊
BLOOD
卷 118, 期 13, 页码 3657-3660出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-02-335497
关键词
-
类别
资金
- INCa (Institut National du Cancer)
- Canceropole Grand Ouest
- Universite de Poitiers
- Universite Paris-Sud 11
- Inserm
- association Laurette Fugain [ALF 09-04]
- Novartis Oncology
- Bristol Myers Squibb
Sustained undetectable molecular residual disease (UMRD) is obtained in a minority of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. It remains unclear whether these patients are definitively cured of their leukemia or whether leukemic stem cells (LSCs) persist in their BM. We have evaluated the presence of BCR-ABL-expressing marrow LSCs in 6 patients with chronic myeloid leukemia with sustained UMRD induced by IFN-alpha (n = 3), imatinib mesylate after IFN-alpha failure (n = 2), and dasatinib after imatinib intolerance (n = 1). Purified CD34(+) cells were used for clonogenic and long-term culture-initiating cell assays performed on classic or HOXB4-expressing MS-5 feeders. Using this strategy, we identified BCR-ABL-expressing LSCs in all patients. Interestingly, long-term culture-initiating cell assays with MS-5/HOXB4 stromal feeders increased detected numbers of LSCs in 3 patients. The relation between LSC persistency and a potential risk of disease relapse for patients with durable UMRD (on or off tyrosine kinase inhibitor therapy) warrants further investigation. (Blood. 2011; 118(13):3657-3660)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据